Statin-related myopathy (SRM), which includes rhabdomyolysis, is an uncommon but important adverse drug reaction because the number of people prescribed statins world-wide is large. Previous association studies of common genetic variants have had limited success in identifying a genetic basis for this adverse drug reaction. We conducted a multi-site whole-exome sequencing study to investigate whether rare coding variants confer an increased risk of SRM.
|Titolo:||Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing|
|Data di pubblicazione:||2019|
|Appare nelle tipologie:||01.01 Articolo in Rivista|